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ABSTRACT
Objectives: This study asked the following questions: 1) Does HIV testing in pregnancy identify
women who previously were not known to be HIV positive? 2) When in pregnancy are women
identified as HIV infected? 3) Does HIV seroconversion occur during the prenatal care period?
Methods: Medical records of 97 women from two primarily indigent care hospitals in Houston,
TX who were found to be HIV positive at delivery were reviewed to determine if they had tested
positive during the prenatal care period. Demographics and time of gestation of the prenatal testing
also were recorded. The outcome measures were: 1) number of women found positive during
prenatal care; 2) week of gestation at discovery of HIV positivity; and 3) number of women
seroconverting between the initiation of prenatal care and delivery.
Results: Thirty women were known to be HIV positive prior to pregnancy. Fifty-six women were
found to be positive during prenatal care and the seropositivity of 44 was discovered before the 34th
week of pregnancy. Ten women were found to be positive at their first prenatal visit, which oc-
curred after the 34th week. Date of testing was unknown for two women. Eleven women who
received no prenatal care were found to be HIV positive at delivery. There were no seroconver-
sions while women were under prenatal care.
Conclusions: HIV testing at delivery did not find any HIV-positive women who had tested
negative during prenatal care. Testing is very important for women who do not receive prenatal
care. Making certain that high-risk women get into prenatal care also is very important. Infect. Dis.
Obstet. Gynecol. 8:172-175, 2000. (C) 2000Wiley-Liss, Inc.
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he American College of Obstetricians and Gy-
necologists, in a joint statement with the
American Academy of Pediatrics, has recom-
mended universal, voluntary counseling and test-
ing for the human immunodeficiency virus (HIV)
for all pregnant women at their first prenatal visit.
The United States Public Health Service also en-
dorsed this recommendation,z Prenatal testing for
HIV also has been recommended as a means of
reducing legal liability.
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These recommendations were based on the
ability to prevent mother-to-child transmission of
HIV. The ACTG 076 trial demonstrated a two-
thirds reduction of mother-to-child transmission of
the human immunodeficiency virus (HIV) can be
achieved by initiating AZT therapy prior to the
34th week of pregnancy, by giving this drug intra-
venously during labor, and by giving the child AZT
following delivery.4 Another study has demon-
strated that administration of zidovudine to the
mother alone in the last few weeks of pregnancy
can reduce the rate of transmission by approxi-
mately 50%.s It also has been shown that giving a
single dose of nevirapine to women at the onset of
labor and to their infants shortly after birth will
reduce the rate of vertical HIV transmission.6 Ob-
stetrical interventions also may reduce transmis-
sion. A meta-analysis showed that the rate of trans-
mission can be reduced further by cesarean
section. 7 It also has been shown that having an
extended period of time between the performance
of amniotomy and delivery increases the risk of
maternal-fetal transmission of HIV.8
An argument can be made for a second screen-
ing for HIV infection at delivery because there is a
14% risk of transmission by breastfeeding.9 There-
fore, knowing that a woman has seroconverted dur-
ing the prenatal care period would allow her phy-
sician to recommend against breastfeeding. In
addition, if a woman who tested negative during
the prenatal period were found to be positive at
delivery, she would have been recently infected.
Many experts advocate treatment early in infection
in order to contain viral replication in the lymphoid
tissue.1 Therefore early detection of seroconver-
sion may have substantial benefit for the mother.
However, the case for conducting HIV testing both
at first prenatal visit and at delivery depends on the
likelihood of seroconversion during the prenatal
care period.
This study was conducted to determine if pre-
viously undiscovered HIV infection could be found
by testing during the prenatal care period. The
study also examined whether HIV infection was
being discovered before the 34th week of gesta-
tion. Discovery before this time would allow full
implementation of the ACTG 076 protocol and/or
sufficient time for antiretroviral therapy to reduce
viral load to a level that reduced the probability of
vertical transmission. In addition, the study exam-
ined the risk of seroconversion between prenatal
testing and delivery.
MATERIALS AND METHODS
The study was conducted at two teaching hospitals
in Houston, Texas. One hospital is a nonprofit, pri-
vate, general hospital, which delivered over 7,000
infants in 1995 and 1996. Seventy percent of these
patients were indigent patients or Medicaid pa-
tients that were serviced by the university-based
obstetrical service. The second hospital is operated
by the county government and serves an exclu-
sively indigent and Medicaid population. All
women delivering at this institution were delivered
in the university-based practice. There were over
11,000 deliveries at this hospital in 1995 and 1996.
It is not known how many women were tested dur-
ing the course of the study. However, during 1995,
the majority of women who delivered at the two
hospitals were offered HIV testing at delivery.
This was almost universal in the university-based
practices but was less likely to be done on the
private service at the private hospital during 1995.
However, the State ofTexas passed a law requiring
that, beginning January 1, 1996, all pregnant
women be offered HIV testing both at their first
prenatal visit and at delivery. 11 Therefore, HIV
testing at delivery was offered to all women during
1996 at both hospitals. No records were kept of the
number of women refusing testing at delivery.
Inpatient and clinic medical records of all
women who tested positive at delivery (defined as
having a repeatedly reactive ELISA confirmed by a
Western blot) were reviewed and data on demo-
graphics, prenatal care, prenatal HIV testing, and
HIV status were abstracted from these records. To
answer the question of whether previously undis-
covered HIV-positive women were identified dur-
ing prenatal care, data were collected on whether
an HIV test was performed during prenatal care
and whether the patient was known to be HIV
positive before pregnancy. Information about the
dates of prenatal care and prenatal HIV testing also
was collected in order to determine if the first HIV
test was conducted before 34 weeks of gestation so
as to initiate the maximally effective antiretroviral
treatment regimen. In addition, the records were
examined to determine if any of the women who
tested positive at delivery had tested negative for
HIV during prenatal care. This was done in order
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TABLE I. Characteristics of study population












Prenatal care (number of subjects)
Some 86
None II
to determine if seroconversion occurred during
pregnancy.
The study was approved by the Committee for
the Protection of Human Subjects at The Univer-
sity of Texas--Houston Health Science Center.
RESULTS
One hundred and one women tested HIV positive
at delivery during the period of 1995 to 1996. For
four of these women, records were incomplete and
were excluded from the study. The characteristics
of the 97 study subjects are shown in Table 1.
Eighty-six of the 97 women who tested positive
at delivery received prenatal care. Of these, 30
were known to be HIV-infected prior to their preg-
nancies so prenatal testing did not provide any new
information. Eleven women did not receive prena-
tal care and their HIV status was first made known
to their obstetrical care providers as a result of the
testing that was done at delivery. Two of the
women who did not receive prenatal care had their
HIV infection discovered through HIV testing that
was done for medical rather than obstetrical rea-
sons. These test results were not available to their
obstetricians prior to delivery.
Of the 56 women who were tested for HIV dur-
ing prenatal care and whose HIV positivity was not
known prior to their pregnancies, 10 received the
results of their HIV test after the 34th week of
pregnancy. For all of these women, the testing was
done at the first prenatal visit. Forty-four women
were tested before the 34th week, which allowed
them to receive the full benefit of antiretroviral
therapy. No patient seroconverted between prena-
tal testing and delivery. Table 2 summarizes these
data.
TABLE 2. Results of testing for HIV in pregnancy
Number of
subjects
Discovery of HIV infection
Known before prenatal care
Identified in prenatal care
Diagnosed at delivery
Timing of HIV discovery during
prenatal care
Known before prenatal care
Before 34 weeks gestation
Between 34 weeks gestation and
delivery
Date of test not recorded
No prenatal care
Effects of testing at delivery
Women testing positive who were
known to be positive before delivery
Newly discovered--No prenatal care
Tested positive at delivery but tested






alncludes two women who were identified as positive while receiving
care for medical reasons. The prenatal providers did not known this
information.
DISCUSSION
The results of this study suggest that HIV screen-
ing in pregnancy in this population will yield a
substantial number of HIV-positive women whose
infection was previously undetected. However, it is
notable that 30 of 97 (31%) women who tested
positive at delivery were already known to be posi-
tive prior to receiving prenatal care.
The finding that there was no seroconversion
during the time from the beginning of prenatal care
and delivery suggests seroconversion might be an
infrequent event. The women in this study were
from two of the three major hospitals serving the
highest risk women in Harris County (Houston).
The HIV-seropositivity rate of women delivering
children in Harris County was 3 per 1,000 deliver-
ies in 1997 and is the highest in the State of
Texas. lz The rate at the two hospitals was approxi-
mately 6 per 1,000 during the study period. There-
fore, if women from this population are not con-
verting from HIV negative to positive between
receiving prenatal care and delivery, it is even less
likely that seroconversion is occurring in other
populations.
The fact that 11 women who did not receive
prenatal care were identified as HIV positive by
screening at delivery emphasizes the importance of
carrying out HIV testing at delivery for women who
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are not tested during the prenatal period. It also
would suggest that rapid HIV testing be made
available routinely in early labor to women who
have not had prenatal care. Otherwise, these wom-
en’s seropositivity will be discovered too late to use
antiretroviral therapy in labor or to avoid early rup-
ture of membranes to prevent maternal-fetal trans-
mission. In the study hospitals, test results usually
were not available until after delivery but were al-
ways available before discharge. However, even if
test results can not be made available in early labor,
there is still value to HIV testing at delivery.
Women who are found to be HIV infected can be
referred for care of the HIV infections. These
women also can be advised not to breastfeed their
children and thereby prevent transmission by that
route. The children of these women can be closely
monitored and will have the opportunity to be
placed on antiretroviral therapy as soon as possible
if they are found to be infected. In addition, early
identification of HIV-positive women also may pre-
vent transmission to their future sexual or needle-
sharing partners.
It is a matter of concern that ten other women
did not have the infection discovered until after the
34th week of pregnancy. As mentioned previously,
the results of the ACTG 076 protocol are based on
starting zidovudine therapy before the 34th week.
This study demonstrates the limits of legislation
such as the Texas law or the various guidelines,
which mandate or recommend the offering of HIV
testing to pregnant women. While these can be
first step, there are a large number of women for
whom this testing will come too late to achieve the
goal of the laws or recommendations. For example,
in this study, 21 of 67 women whose HIV infection
was not known prior to pregnancy did not receive
any prenatal care or received prenatal care so late in
pregnancy that maximally effective therapy could
not be utilized. Therefore, making certain that
women are receiving prenatal care as early as pos-
sible is an extremely important factor in determin-
ing whether or not HIV transmission in pregnancy
is reduced to its lowest possible level. This means
that additional efforts must be devoted to making
certain that prenatal services are easily accessible
for pregnant women who are at high risk for HIV
infection. In addition, community education pro-
grams that encourage high-risk women to seek pre-
natal care at the earliest possible time in pregnancy
need to be developed or enhanced. Otherwise, the
potential for reduction of maternal-fetal transmis-
sion of HIV infection will only be partially realized.
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